Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to -$31.0 million.

  • Tango Therapeutics' Cash from Operations rose 730.16% to -$31.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$145.8 million, marking a year-over-year decrease of 1920.68%. This contributed to the annual value of -$131.5 million for FY2024, which is 1145.85% down from last year.
  • Latest data reveals that Tango Therapeutics reported Cash from Operations of -$31.0 million as of Q3 2025, which was up 730.16% from -$36.5 million recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' Cash from Operations ranged from a high of -$7.5 million in Q2 2021 and a low of -$41.7 million during Q1 2025
  • In the last 5 years, Tango Therapeutics' Cash from Operations had a median value of -$29.7 million in 2022 and averaged -$27.8 million.
  • As far as peak fluctuations go, Tango Therapeutics' Cash from Operations plummeted by 2349365000.0% in 2021, and later soared by 2240.15% in 2023.
  • Over the past 5 years, Tango Therapeutics' Cash from Operations (Quarter) stood at -$16.9 million in 2021, then tumbled by 67.23% to -$28.3 million in 2022, then grew by 2.83% to -$27.5 million in 2023, then crashed by 33.42% to -$36.6 million in 2024, then increased by 15.54% to -$31.0 million in 2025.
  • Its Cash from Operations stands at -$31.0 million for Q3 2025, versus -$36.5 million for Q2 2025 and -$41.7 million for Q1 2025.